Recommended
Recommended
More Related Content
What's hot
What's hot (20)
Similar to Amgen's Digital Worker Journey
Similar to Amgen's Digital Worker Journey (20)
Recently uploaded
Recently uploaded (20)
Amgen's Digital Worker Journey
- 1. 2019 DIGITAL WORKER @ AMGEN
- 2. 2 One of the world’s leading independent biotechnology companies ~ 100 countries Reached millions of patients AMGEN TODAY
- 3. 3 PRODUCTS For additional information about Amgen products, including important safety information, please visit amgen.com Note: Aimovig™ is developed in collaboration with Novartis
- 5. 5 Passionate about innovation, and the opportunity automation provides • Originally from India, but grew up in UAE • Technology leader at Amgen leading Automation, Integration & Development capabilities spanning 10 technologies • Worked at Amgen since 2008 • Platform owner of AA Platform & technology road map • Technology lead for Corporate Initiative around Intelligent Automation ABOUT ME
- 6. 6 Amgen Proprietary—For Internal Use Only AMGEN’S RPA JOURNEY Research and Development Process Development/ Manufacturing Regulatory / Safety / Compliance Back-office Administrative Sales, Marketing, and Life Cycle Management 1 automations in Research 4 automations in PD/Manufacturing 20 automations in Finance & Accounting 2 automations in Sales/Marketing & commercial 6 automations around Compliance 2 automations in HR and Back-Office • Implemented Automation Anywhere initially in 2010, first 7 years focused on pure IT automation • Focus on pure RPA initiated in 2017 with formal program kicked off to govern demand in 2018 • 35 automations built across multiple functions • Amgen currently leveraging AA 11.3.1 • Current focus of building an Intelligent Automation Product team
- 7. 7 Digital worker is a persona that has similar capabilities at workplace like a human • Digital worker set of professional skills that enable it to act, process, and analyze in the same ways as a human • Digital worker will automate entire processes, do multiple tasks in a set of sequences • Workplace of the Future = Humans + Digital Worker WHAT IS A DIGITAL WORKER
- 9. 9Cost to maintain Bots a big factor in reducing NPV for automations • Reduce cycle time by standardizing access persona(s) • Enables governance and utilization monitoring • Reduce cost of ownership • Improves human engagement BECAUSE …..
- 10. 10 Future interactions could leverage Alexa/Google Digital Workers can operate based on: • A schedule • Human interactions (email, chat, voice, etc.) • System or Digital Worker interactions MULTIPLE MODES OF ENGAGEMENT
- 11. 11 • Leverage HR systems to request and manage Digital workers • Reduce time to market for automations leveraging Digital worker • Propose labor & benefit for Digital workers that helps pay for upkeep of Digital worker including licenses & infrastructure • Supplement need for additional human head count by offering Digital worker head count, thus reducing operational expenses for companies VISION
- 12. 12 Important to have all stakeholders on board while embarking on this aspiration • Lead time and alignment with HR organization on board to create new employee type – Digital workers • Lead time and alignment with- Identity management organization to support access to Digital worker – long lead time • Re-Design access process to systems for Digital workers • Controls around Digital workers CHALLENGES
- 13. 13 • HR system(Workday) used to onboard Digital workers • COE reviews request to ensure existing digital workers cannot be leveraged for automations HR SYSTEM
Editor's Notes
- Founded in 1980, Amgen has grown to be one of the world’s largest independent biotechnology companies. We have a presence in approximately 100 countries. And we’ve reached millions of people with our medicines.
- We have 16 medicines on the market today (U.S.)… EPOGEN: First blockbuster Treats lower than normal number of red blood cells (anemia) caused by chronic kidney disease in patients on dialysis Acts like the hormone erythropoietin It helps the body create more red blood cells, which raises the hemoglobin (Hb) level Prescribed for more than 20 years NEUPOGEN: Used to reduce the risk of infection in patients with some tumors receiving strong chemotherapy that may cause severe neutropenia (nu-tro-peen-ee-ah) with fever Neutropenia is when the body makes too few neutrophils (nu-tro-fils), a type of white blood cell that helps fight infection. G-CSF (granulocyte colony-stimulating factor) is a substance naturally produced by the body that stimulates the growth of neutrophils NEUPOGEN is a man-made form of G-CSF made using the bacteria Escherichia coli ARANESP: Similar to EPO but longer lasting than EPO Approved for treatment of anemia in patients with chronic kidney disease (not just dialysis as with EPO) or anemia caused by chemotherapy that will be used for at least two months after starting Aranesp NEULASTA: A G-CSF like Neupogen, but longer lasting ENBREL: Used to treat multiple long-term inflammatory diseases including moderate to severe rheumatoid arthritis (RA) Tumor necrosis factor (TNF) is a substance made by your body's immune system People with inflammatory diseases like rheumatoid arthritis have too much TNF in their bodies ENBREL reduces levels of the active form of TNF SENSIPAR / MIMPARA: Indicated for the treatment of secondary hyperparathyroidism (HPT) in patients with chronic kidney disease (CKD) on dialysis Sold by Amgen under the trade name Sensipar in North America and Australia and as Mimpara in Europe One of the few small molecule (pill) medicines sold by Amgen It works on parathyroid glands to release less calcium and phosphorus into bones VECTIBIX: Indicated for the treatment of patients with certain types of colorectal cancer Targets the epidermal growth factor receptor (EGFR), a protein that plays an important role in cancer cell signaling It binds to the EGFR receptor, interfering with the signals that might otherwise stimulate growth and survival of the cancer cell NPLATE: Indicated for treatment of thrombocytopenia in patients with chronic immune thrombocytopenia (ITP) in certain instances Nplate is a peptibody protein, a novel platform developed by scientists at Amgen A peptibody is an engineered protein, made by recombinant DNA technology, with attributes of both peptides and antibodies Designed to bind to the thrombopoeitin (TPO) receptor thereby stimulating platelet production PROLIA: Used to treat osteoporosis in women after menopause at high risk for fracture It helps stop the development of bone-removing cells (osteoclasts) before they can reach and damage the bone Prolia inhibits RANKL from activating its receptor, RANK, on the surface of osteoclasts and their precursors XGEVA: Indicated for the prevention of skeletal-related events in patients with bone metastases from solid tumors Like Prolia, inhibits RANKL from activating its receptor, RANK on the surface of osteoclasts, thereby decreasing bone destruction
- Our focus is on six therapeutic areas: Oncology/Hematology Cardiovascular Disease Inflammation Bone Health Nephrology Neuroscience